5-chloro-2-methyl-7H-isoxazolo[2,3-a]pyrimidin-7-one | 278614-92-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-chloro-2-methyl-7H-isoxazolo[2,3-a]pyrimidin-7-one
• 英文别名: 5-chloro-2-methyl-[1,2]oxazolo[2,3-a]pyrimidin-7-one
• CAS: 278614-92-9
• 化学式: C₇H₅ClN₂O₂
• mdl: MFCD07366359
• 分子量: 184.582
• InChiKey: XNAWHAKTUSSDKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  哌嗪 、 5-chloro-2-methyl-7H-isoxazolo[2,3-a]pyrimidin-7-one 以 乙醇 为溶剂， 反应 1.0h， 以42%的产率得到2-Methyl-5-piperazin-1-yl-isoxazolo[2,3-a]pyrimidin-7-one
  参考文献：
  名称：

  Synthesis, antiplatelet activity and comparative molecular field analysis of substituted 2-amino-4 H -pyrido[1,2- a ]pyrimidin-4-ones, their congeners and isosteric analogues

  摘要：

  2-(1-Piperazinyl)-4H-pyrido[1,2-a]pyrimidin-4-one (5a) is a recently described in vitro inhibitor of human platelet aggregation which specifically inhibits the activity of high affinity cAMP phosphodiesterase. A number of substitution derivatives, isosteres, and analogues of 5a were now synthesized and tested in vitro for their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca2+ ionophore A23187. Among the most effective compounds, the 6-methyl, 8-methyl and 6,8-dimethyl derivatives of 5a resulted nearly as active as the lead when platelet aggregation was induced by ADP or A23187, but less active when collagen was the inducer. On the basis of present results and those previously obtained by us in this and 2-aminochromone structural fields, we have developed a statistically significant 3-D QSAR model, using comparative molecular field analysis (CoMFA), describing the variation of the antiplatelet activity in terms of molecular steric and electrostatic potential changes. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00010-9
• 作为产物：
  描述：

  3-[(5-甲基-1,2-恶唑-3-基)氨基]-3-氧代丙酸乙酯 在 PPA 、 三氯氧磷 作用下， 反应 1.0h， 以34%的产率得到5-chloro-2-methyl-7H-isoxazolo[2,3-a]pyrimidin-7-one
  参考文献：
  名称：

  Synthesis, antiplatelet activity and comparative molecular field analysis of substituted 2-amino-4 H -pyrido[1,2- a ]pyrimidin-4-ones, their congeners and isosteric analogues

  摘要：

  2-(1-Piperazinyl)-4H-pyrido[1,2-a]pyrimidin-4-one (5a) is a recently described in vitro inhibitor of human platelet aggregation which specifically inhibits the activity of high affinity cAMP phosphodiesterase. A number of substitution derivatives, isosteres, and analogues of 5a were now synthesized and tested in vitro for their inhibitory activity on human platelet aggregation induced in platelet-rich plasma by ADP, collagen, or the Ca2+ ionophore A23187. Among the most effective compounds, the 6-methyl, 8-methyl and 6,8-dimethyl derivatives of 5a resulted nearly as active as the lead when platelet aggregation was induced by ADP or A23187, but less active when collagen was the inducer. On the basis of present results and those previously obtained by us in this and 2-aminochromone structural fields, we have developed a statistically significant 3-D QSAR model, using comparative molecular field analysis (CoMFA), describing the variation of the antiplatelet activity in terms of molecular steric and electrostatic potential changes. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00010-9

文献信息

• [EN] 1,4-DIAZABICYCLO[3.2.2]NONANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] 1,4-DIAZABICYCLO[3.2.2]NONANES EN TANT QUE LIGANDS DU RÉCEPTEUR NICOTINIQUE NEURONAL DE L'ACÉTYLCHOLINE
  申请人：TARGACEPT INC

  公开号：WO2013028587A1

  公开（公告）日：2013-02-28

  The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including inflammatory diseases and diseases associated with dysfunction of the central nervous system (CNS).

  本发明涉及结合并调节神经元尼古丁型乙酰胆碱受体活性的化合物，涉及制备这些化合物的方法，含有这些化合物的药物组合物，以及利用这些化合物治疗各种疾病和紊乱的方法，包括炎症性疾病和与中枢神经系统（CNS）功能障碍相关的疾病。
• 1,4-DIAZABICYCLO[3.2.2]NONANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Mazurov Anatoly

  公开号：US20140249141A1

  公开（公告）日：2014-09-04

  The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including inflammatory diseases and diseases associated with dysfunction of the central nervous system (CNS).

  本发明涉及与神经尼古丁乙酰胆碱受体结合并调节其活性的化合物，涉及制备这些化合物的过程，包含这些化合物的制药组合物，以及使用这些化合物治疗各种疾病和疾病的方法，包括炎症性疾病和与中枢神经系统（CNS）功能障碍相关的疾病。